In summary our intriguing and novel results point to the potential broader utility of PARP inhibitors in breast cancer beyond hereditary BRCA1-and BRCA2-deficient tumors by combining it with EGFR inhibitors such as lapatinib. This evidence concerns the gene BRCA2 and breast cancer.